In light of those facts, and considering how many more years to go before human trial would produce approvable results, I question how you arrived at the conclusion that "they shouldn't run out of cash".
Latest report from ibx states $7 million in cash left, burning $1 million/quarter PLUS costs of outsourcing which will include the large tasks of designing and building a human machine and the manufacturing of nano particles. Then add in the costs of trials to prove the safety and efficacy you mentioned, and the cost of human trials.
Anyone wondering why the ibx price has fallen need only look at the cash requirements to get from here to the end of human trials and it should be clear that the $7 million won't last very long and that further substantial dilution is inevitable.
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM